A long-suffering Clovis makes a leap into radiopharmaceuticals, paying $12M in cash to beef up the pipeline
In the 17 months since Clovis won an approval for their PARP drug Rubraca, the reality of anemic sales revenue against a backdrop of major …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
